Ces radiol. 2016, 70(4):219-227 | DOI: 10.55095/CesRadiol2016/029

Hybrid imaging of liver and pankreas using PET/MRIReview article

Jiří Ferda, Eva Ferdová, Jan Baxa

Klinika zobrazovacích metod LF UK a FN, Plzeň

Hybrid imaging using PET/MRI in liver and pancreas uses the enhanced tissue contrast of magnetic resonance including dynamic enhancement using gadolinium based contrast agent with early extracellular and late hepatospecific distribution with addition of the evaluation of the metabolic activity of the tissues. The possibility of the synchronous data acquisition with the breathing movements improves the detectability of the presence and level of the metabolic activity within the lesions. ¹⁸F-fluorodeoxyglucose is being an optimal radiopharmaceutical in detection and follow-up of the liver metastases and cholangiogenous tumors. The hepatocellular carcinoma imaging could be based both on the ¹⁸F-fluorodeoxyglucose and ¹⁸F-fluorocholine. I tis the advantage to combine magnetic resonance and positron emission tomography in patients with pancreatic tumors, including the assessment of the behavior and in the evaluation of the staging of the tumor, especially in cases when the hepatic metastases of pancreatic tumors should be excluded. In tumors of neuroendocrine origin even in pancreatic or liver secondary tumors, the useful radiopharmaceutical is ¹⁸F-fluorodihydroxyphenylalanine.

Keywords: hybrid imaging, PET/MRI, liver tumors, pancreatic tumors

Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: December 15, 2016; Published: December 1, 2016  Show citation